moneyheap
ICLR · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Icon Plc (ICLR) stock moving?
ICLR jumped 17% on Oct 28, closing at $214.16 from $182.98 on volume of 3.95M, roughly four times its typical daily level, after Q3 2026 results. Eight brokers that published targets raised them to between $215 and $268, with an average near $241, about 18% above the Nov 10 close. Five of the eight rate the stock Buy or Outperform (Truist, TD Cowen, Baird, RBC, Deutsche Bank), while UBS, Barclays and Citi stay Neutral or Equal-Weight. Since the peak of $219.04 on Oct 29, the shares have eased to $204.63 on Nov 10, about 4% below the post-earnings close, and volume has fallen to 617K, the lowest of the recent sessions. The price remains about 12% above the pre-earnings close. The supplied filing text lacks the Q3 revenue, margin and guidance figures, so the case rests on analyst reactions and the price reaction. The only other filing, dated Nov 10, is a routine investor-conference notice.
News behind the analysis
- Form 6-K: ICON reports Third Quarter 2026 resultsICON filed its Q3 2026 results press release with the SEC as Exhibit 99.1. The filing text supplied here does not include the figures.
- Analysts Adjust Price Targets for ICON Public Limited Company Following Q3 EarningsSeveral brokers, including Deutsche Bank, RBC and Truist, raised their price targets after the Q3 2026 earnings call.
- TD Cowen Maintains Buy on Icon, Raises Price Target to $254TD Cowen kept its Buy rating and lifted its target to $254 after Q3 results.
- Truist Securities Maintains Buy on Icon, Raises Price Target to $268Truist kept its Buy rating and set the highest target in the set at $268.
- RBC Capital Maintains Outperform on Icon, Raises Price Target to $226RBC kept its Outperform rating and raised its target to $226.
- Baird Maintains Outperform on Icon, Raises Price Target to $249Baird kept its Outperform rating and raised its target to $249.
- UBS Maintains Neutral on Icon, Raises Price Target to $236UBS kept a Neutral rating and raised its target to $236.
- Barclays Maintains Equal-Weight on Icon, Raises Price Target to $230Barclays kept an Equal-Weight rating and raised its target to $230.
- Citigroup Maintains Neutral on Icon, Raises Price Target to $215Citigroup kept a Neutral rating and raised its target to $215, the lowest in the set.
- Form 6-K: ICON to Participate at Upcoming Investor ConferencesICON filed notice that it will take part in upcoming investor conferences. This is a routine corporate update.
About Icon Plc
ICON plc is a contract research organization (CRO) based in Dublin, Ireland. Drug, biotech and medical device companies hire it to run their clinical trials, and it is one of the largest companies in this field, with roughly 40,000 employees in about 55 countries and annual revenue of around $8 billion.
How it makes money
ICON is paid to run outsourced clinical development work for its clients. This includes designing and managing clinical trials, recruiting trial sites and patients, running central labs, handling data and statistics, and giving regulatory and consulting advice. Most contracts cover several years. They are signed as bookings and then added to a backlog, which recently stood at roughly $23 billion. Revenue also includes 'pass-through' costs that ICON pays on clients' behalf and bills back to them, such as payments to investigator sites. These costs add to revenue but earn little profit. Large pharmaceutical companies make up much of its client base, with smaller biotechs making up the rest. Management's 2026 revenue guidance was roughly $7.85 to $8.15 billion. Profit margins fell in 2026 compared with 2025.
What usually moves ICLR
- Pharma and biotech R&D and outsourcing budgets
- Biotech funding conditions and trial cancellations
- New bookings, book-to-bill ratio and backlog
- Profit margin trends and the mix of pass-through revenue
- Drug-pricing policy and regulatory changes